Cargando…

Incretin concept revised: The origin of the insulinotropic function of glucagon‐like peptide‐1 – the gut, the islets or both?

Incretins comprise a pair of gut hormones, glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1), which are secreted in response to food ingestion and enhance glucose‐dependent insulin secretion from pancreatic β‐cells. Immediately after secretion, GLP‐1 is degraded...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yabe, Daisuke, Seino, Yusuke, Seino, Yutaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754537/ https://www.ncbi.nlm.nih.gov/pubmed/28746743 http://dx.doi.org/10.1111/jdi.12718

Ejemplares similares

Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1: Incretin actions beyond the pancreas
por: Seino, Yutaka, et al.
Publicado: (2013)

Carbohydrate‐induced secretion of glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1
por: Seino, Yusuke, et al.
Publicado: (2016)

Cardiovascular safety trials of incretin‐based drugs: What do they mean?
por: Yabe, Daisuke, et al.
Publicado: (2016)

GIP and GLP‐1, the two incretin hormones: Similarities and differences
por: Seino, Yutaka, et al.
Publicado: (2010)

The journey to understanding incretin systems: Theory, practice and more theory
por: Yabe, Daisuke, et al.
Publicado: (2019)

Incretin‐based drugs for type 2 diabetes: Focus on East Asian perspectives
por: Seino, Yutaka, et al.
Publicado: (2016)

Fructose induces glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and insulin secretion: Role of adenosine triphosphate-sensitive K(+) channels
por: Seino, Yusuke, et al.
Publicado: (2015)

Roles of glucose‐dependent insulinotropic polypeptide in diet‐induced obesity
por: Seino, Yusuke, et al.
Publicado: (2022)

Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study
por: Kuwata, Hitoshi, et al.
Publicado: (2021)

Tumor‐like features of gene expression and metabolic profiles in enlarged pancreatic islets are associated with impaired incretin‐induced insulin secretion in obese diabetes: A study of Zucker fatty diabetes mellitus rat
por: Hayami, Tomohide, et al.
Publicado: (2020)

The Incretins and Pancreatic β-Cells: Use of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide to Cure Type 2 Diabetes Mellitus
por: Kim, Mi-Hyun, et al.
Publicado: (2010)

Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial
por: Kuwata, Hitoshi, et al.
Publicado: (2015)

Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes
por: Yabe, Daisuke, et al.
Publicado: (2011)

SAT037 Glucagon-like Peptide-1 Receptor Knockout Mice Do Not Compensate For The Lack Of Incretin Action By Increasing Glucose-dependent Insulinotropic Polypeptide Secretion
por: Douglas Galsgaard, Katrine, et al.
Publicado: (2023)

The Origin and Understanding of the Incretin Concept
por: Rehfeld, Jens F.
Publicado: (2018)

The Incretin Effect in Female Mice With Double Deletion of GLP-1 and GIP Receptors
por: Ahrén, Bo, et al.
Publicado: (2019)

Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference
por: Yabe, Daisuke, et al.
Publicado: (2011)

Dipeptidyl peptidase‐4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?
por: Yabe, Daisuke, et al.
Publicado: (2014)

Dipeptidyl peptidase‐4 inhibitors and prevention of bone fractures: Effects beyond glyemic control
por: Yabe, Daisuke, et al.
Publicado: (2012)

β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians
por: Yabe, Daisuke, et al.
Publicado: (2015)

Glucagon-like peptide 1 and dysglycemia: Conflict in incretin science
por: Singh, Awadhesh Kumar
Publicado: (2015)

Sodium‐glucose cotransporter‐2 inhibitor luseogliflozin added to glucagon‐like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52‐week, open‐label, single‐arm study
por: Seino, Yutaka, et al.
Publicado: (2017)

Mechanisms underlying glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 secretion
por: Reimann, Frank, et al.
Publicado: (2016)

Carbohydrate‐induced weight gain models for diabetes research: Contribution of incretins and parasympathetic signal
por: Seino, Yusuke, et al.
Publicado: (2020)

Regulation of amino acid metabolism and α‐cell proliferation by glucagon
por: Hayashi, Yoshitaka, et al.
Publicado: (2018)

Little enhancement of meal‐induced glucagon‐like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls
por: Yabe, Daisuke, et al.
Publicado: (2010)

Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 secretion in humans: Characteristics and regulation
por: Alsalim, Wathik, et al.
Publicado: (2022)

Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity
por: Usui, Ryota, et al.
Publicado: (2019)

The Asian Association for the Study of Diabetes: The first 10 years and the next 10 years
por: Seino, Yutaka, et al.
Publicado: (2020)

Gastrointestinal Incretins—Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Disease—State of the Art
por: Jonik, Szymon, et al.
Publicado: (2022)

Blockade of glucagon increases muscle mass and alters fiber type composition in mice deficient in proglucagon‐derived peptides
por: Ueno, Shinji, et al.
Publicado: (2023)

Incretin Concepts
por: Bloomgarden, Zachary T.
Publicado: (2010)

The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action
por: Hare, Kristine J., et al.
Publicado: (2010)

The once‐daily human glucagon‐like peptide‐1 analog, liraglutide, improves β‐cell function in Japanese patients with type 2 diabetes
por: Seino, Yutaka, et al.
Publicado: (2012)

Stimulatory effect of imeglimin on incretin secretion
por: Yingyue, Quan, et al.
Publicado: (2023)

Effects of DPP‐4 inhibitor linagliptin and GLP‐1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open‐label, 2‐arm parallel comparative, exploratory trial
por: Yabe, Daisuke, et al.
Publicado: (2016)

β‐Cell glutamate signaling: Its role in incretin‐induced insulin secretion
por: Yokoi, Norihide, et al.
Publicado: (2016)

Investigation of endothelial nitric oxide (NO) signalling in response to the incretin hormone glucose-dependent insulinotropic polypeptide (GIP)
por: Savage, PJ, et al.
Publicado: (2012)

Glucagon‐like peptide‐1 and glucose‐dependent insulinotropic peptide: effects alone and in combination on insulin secretion and glucose disappearance in mice
por: Pacini, Giovanni, et al.
Publicado: (2017)

Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
por: Zaffina, Isabella, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bok3887prglsth990p1ql48nt6